Genetic heterogeneity in HER2 testing may influence therapy eligibility
Barbara Bernasconi(Ospedale di Circolo e Fondazione Macchi), Maria Grazia Tibiletti(University of Insubria), Katia Milani(University of Insubria), Giovanna Finzi(Ospedale di Circolo e Fondazione Macchi), Anna Maria Chiaravalli(Ospedale di Circolo e Fondazione Macchi)
Cited by 34
Related Papers
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
|Oncotarget|2016|309
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
|British Journal of Haematology|2005|193
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
|Blood|2010|189
Inheritance in idiopathic premature ovarian failure: analysis of 71 cases
|Human Reproduction|1998|166